Marquet Magda 4

What Happened

• Magda Marquet, a member of Arcturus Therapeutics Holdings Inc.'s board of directors, was granted a derivative award for 15,000 shares on 2026-06-05. The award shows an acquisition price of $0.00 (i.e., a grant of equity-based compensation rather than a cash purchase).
• The filing indicates this is the 2026 annual board grant to the reporting person; the underlying shares/options vest monthly over a one-year period.

Key Details

• Transaction date: 2026-06-05; Filing date: 2026-06-15 (filed 10 days after the transaction).
• Instrument and amount: Award/derivative grant of 15,000 shares; reported price $0.00.
• Vesting: Shares underlying the option vest monthly over one year from grant date (footnote F1).
• Shares owned after transaction: Not specified in the information provided in this summary.
• Timeliness: The Form 4 was filed 10 days after the reported transaction; Form 4s are normally due within two business days, so this appears to be a late filing.

Context

• This was a compensation grant to a director (not an open-market purchase or sale). Such awards are routine for board members and reflect compensation, not necessarily a buy/sell signal about the company.
• Because the grant vests over time, the director does not receive all shares immediately; vesting aligns incentives but does not represent an immediate change in market position.